MAO-A
Monoamine oxidase A (MAO-A) is a mitochondrial flavin-dependent enzyme that catalyzes the oxidative deamination of monoamine neurotransmitters and thereby regulates neurotransmitter homeostasis in the nervous system and peripheral tissues[1]. Mechanistically, MAO-A metabolizes serotonin and norepinephrine and contributes to dopamine turnover, generating aldehydes, ammonia, and hydrogen peroxide as metabolic by-products that influence cellular redox status and downstream biological responses[1][2]. Through its control of monoamine catabolism, MAO-A participates in neuropsychiatric and neurodegenerative pathways and has therefore become an important molecular target in neuroscience and drug discovery research[2][3]. In disease-related experimental systems, altered MAO activity has been associated with oxidative stress and tissue dysfunction, while pharmacological inhibition of MAO can modify neurotransmitter metabolism and related physiological outcomes[2][4]. Compared with the closely related isoform MAO-B, MAO-A shows higher substrate preference for serotonin and norepinephrine, whereas MAO-B preferentially metabolizes phenylethylamine and contributes differently to monoamine turnover, making isoform selectivity a critical consideration in experimental design and therapeutic development[3][5]. For experimental applications, selective MAO-A inhibitors such as clorgyline and moclobemide are widely used to investigate monoamine signaling, neurotransmitter metabolism, and MAO-dependent biological mechanisms, while reversible and irreversible inhibitor classes provide complementary pharmacological tools for mechanistic studies[4][2].
References:
- [1]. Wang CC, et al. Monoamine oxidases in development. Cell Mol Life Sci. 2013 Feb;70(4):599-630. [Content Brief]
- [2]. Manzoor S, et al. A comprehensive review of monoamine oxidase inhibitors as Anti-Alzheimer's disease agents: A review. Eur J Med Chem. 2020;206:112787.
- [3]. Ribeiro LV, et al. Monoamine Oxidase Inhibitors in Drug Discovery Against Parkinson's Disease: An Update. Pharmaceuticals (Basel). 2025;18(10):1526.
- [4]. Lighezan R, et al. Monoamine oxidase inhibition improves vascular function in mammary arteries from nondiabetic and diabetic patients with coronary heart disease. Can J Physiol Pharmacol. 2016;94(10):1040-1047.
- [5]. Brannan T, et al. In vivo comparison of the effects of inhibition of MAO-A versus MAO-B on striatal L-DOPA and dopamine metabolism. J Neural Transm Park Dis Dement Sect. 1995;10(2-3):79-89. [Content Brief]
All Product Categories
-
MAO-A Related Products (137)
Related Products (137)
-
MAO-B-IN-18
0 ImagesMAO-B-IN-18 is a potent and selective MAO B inhibitor with IC50s of 52 nM and 14 μM for hMAO B and hMAO A, respectively. MAO-B-IN-18 enables promising cytoprotective effects against hydrogen peroxide insults in neuroblastoma and astrocytes cultures.
-
2-APB hydrochloride
0 Images2-APB is an analog of 6-APB, a benzofuran derivative and a psychoactive substance. Certain benzofuran derivatives have monoamine oxidase-A inhibitory activity .
-
MAO A/HDAC-IN-1
0 ImagesCat. No.: HY-142706CAS No.: 3031466-56-2MAO A/HDAC-IN-1 is a dual?inhibitor?of monoamine oxidase A (MAO A) and HDAC. MAO A/HDAC-IN-1 can be used for glioma research. MAO A/HDAC-IN-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
-
RS 2232
0 ImagesCat. No.: HY-123129CAS No.: 85073-83-2RS 2232 is an orally active, competitive 5-HT deamination inhibitor with a Ki of 0.054 μM. RS-2232 exhibits reversible and specific inhibition of type A monoamine oxidase. RS 2232 can be used in brain research.
-
MAO-B-IN-39
0 ImagesCat. No.: HY-170887CAS No.: 3094045-97-0MAO-B-IN-39 (compound11) is a selective monoamine oxidase B (MAO-B) inhibitor. MAO-B-IN-39 inhibits MAO-Bwith an IC50 of 3.61 μM. MAO-B-IN-39 demonstrates a potent NRF2 induction capacity. MAO-B-IN-39 exhibits potent anti-inflammatory and neuroprotective activity in OS (oxidative stress)-related in vitro models. MAO-B-IN-39 demonstrates high liver microsomal stability and favorable pharmacokinetics in mice. MAO-B-IN-39 is potential for Parkinson’s disease (PD) research.
-
MAO-B-IN-37
0 ImagesCat. No.: HY-168728CAS No.: 894280-02-5MAO-B-IN-37 (Compound 37) is a derivative of TT01001 (HY-114520), and a selective inhibitor for monoamine oxidase B (MAO-B) with an IC50 of 270 nM. MAO-B-IN-37 exhibits good metabolic stability in mice microsomes and good affinity with human serum albumin.
-
Ro 41-1049
0 ImagesCat. No.: HY-100027CAS No.: 127500-84-9Ro 41-1049 is a highly selective, reversible MAO-A inhibitor. Ro 41-1049 effectively blocks the Quinpirole (HY-B1752)-induced increase in dopamine D2-like receptor density in the nucleus accumbens and alters the pattern of behavioral sensitization, shifting animals' responses from enhanced motor activity to immobile self-directed gaping behavior. Tritium-labeled Ro 41-1049 serves as a high-affinity radioligand, enabling accurate mapping of the distribution and abundance of MAO-A in the central nervous system, peripheral organs, and human brain via quantitative enzyme autoradiography. Ro 41-1049 can be used for basic research on depression and other related diseases.
-
MAO-A inhibitor 2
0 ImagesCat. No.: HY-163322MAO-A inhibitor 2 (compound HT4) is a monoamine oxidase A (MAO-A) inhibitor with an IC50 of 14.3 µM. MAO-A inhibitor 2 shows a less effect on MAO-B (IC50 of 106 µM) and shows almost ineffective on xanthine oxidase (XO). MAO-A inhibitor 2 can be used for the neurodegenerative disorders and oxidative stress research.
-
ChEs/MAOs-IN-2
0 ImagesCat. No.: HY-158092CAS No.: 693268-77-8ChEs/MAOs-IN-2 (compound a11) is a cholinesterases and monoamine oxidases inhibitor with IC50 values of 0.10, 0.20, 0.30, 0.40 µM for MAO-A, MAO-B, AChE, and BChE, respectively. ChEs/MAOs-IN-2 has the potential for the research of Alzheimer's disease.
-
LSD1-IN-17
0 ImagesCat. No.: HY-144758CAS No.: 3033060-70-4LSD1-IN-17 (compound 5b) is a potent LSD1 inhibitor. LSD1-IN-17 can inhibit LSD1-CoREST, MAO-A and MAO-B, with IC50 values of 0.005, 0.028, and 0.820 μM, respectively. LSD1-IN-17 displays cell growth arrest in prostate cancer LNCaP cells, with an IC50 of 17.2 μM.
-
MAO-B-IN-56
0 ImagesCat. No.: HY-182786MAO-B-IN-56 is a multi-target-directed ligand with AChE, BChE, MAO-B, and BACE1 inhibitory activity, with IC50 values of 0.35 μM, 3.22 μM, 0.14 μM, and 3.85 μM respectively, and shows selectivity for AChE over BChE and MAO-B over MAO-A.MAO-B-IN-56 reduces amyloid-beta production, reduces paw edema, improves spatial memory, and enhances Alzheimer's disease hallmarks and associated histopathological alterations.MAO-B-IN-56 can be used for the research of alzheimer's disease.
-
Cimoxatone
0 ImagesSynonyms: MD 780515Cimoxatone (MD 780515) is a reversible, selectively and orally active type A monoamine oxidase (MAO-A) inhibitor. Cimoxatone enhances the anorectic action of Serotonin (HY-B1473A).
-
LSD1-IN-34
0 ImagesCat. No.: HY-162729CAS No.: 3048029-74-6LSD1-IN-34 (Compound 7d) is the orally active inhibitor for Lysine-specific demethylase (LSD) and monoamine oxidase (MAO), with IC50 of 4.51 and 18.46 nM, for LSD1 and MAO A. LSD1-IN-34 inhibits the Ang II-induced neonatal rat myocardial fibroblasts (NRCFs) activation, without significant toxicity (20 μM). LSD1-IN-34 inhibits TGFβ/Smad signaling pathway, and ameliorates heart failure in mice. LSD1-IN-34 exhibits good pharmacokinetic characteristics in rats.
-
MAO-B-IN-33
0 ImagesCat. No.: HY-158732CAS No.: 2286257-25-6MAO-B-IN-33 (compound C3) is a potent, reversible and selective monoamine oxidase-B (MAO-B) inhibitor with an IC50 of 0.021 μM and 26.805 μM for MAO-B and MAO-A, respectively. The selectivity of MAO-B-IN-33 is attributed to the steric clash arising from the residue differences between Phe208 (MAO-A) and Ile199 (MAO-B). MAO-B-IN-33 inhibits cerebral MAO-B activity and alleviates MPTP (HY-15608)-induced dopaminergic neuronal loss in the mouse. MAO-B-IN-33 has the potential for Parkinson's disease research.
-
BChE/MAO-A-IN-1
0 ImagesCat. No.: HY-179126BChE/MAO-A-IN-1 (compound 7j) is a BChE/MAO-A inhibitor. BChE/MAO-A-IN-1 exhibits inhibitory activity against BChE (IC50 = 0.03 nM) and MAO-A (IC50 = 0.32 nM), while also having inhibitory effects on MAO-B. BChE/MAO-A-IN-1 has good anti glycation, antioxidant activity, and low cytotoxicity. BChE/MAO-A-IN-1 can be used in the research of diabetes and Alzheimer's disease.
-
MAO-B-IN-16
0 ImagesCat. No.: HY-151208CAS No.: 1021238-13-0MAO-B-IN-16 is a selective monoamine oxidase B (MAO-B) inhibitor, with an IC50 of 1.55 µM. MAO-B-IN-16 can be used in the study of central nervous disorders, such as parkinson's disease.
-
BChE/MAO-B-IN-2
0 ImagesCat. No.: HY-175524BChE/MAO-B-IN-2 is a dual inhibitor of BChE (IC50 = 0.05 μM, Ki = 0.01 μM) and MAO-B (IC50 = 0.45 μM, Ki = 0.08 μM) with good blood-brain barrier permeability. BChE/MAO-B-IN-2 exhibits antioxidant activity, including DPPH radical scavenging, CUPRAC copper ion reduction, and superoxide anion scavenging. BChE/MAO-B-IN-2 can be used for the study of Alzheimer's disease (AD).
